About Us

Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development.

Founded in September 2015 in Irvine, California, USA, Cloudbreak Therapeutics quickly advanced our first drug candidate through lead selection, pre-clinical IND-enabling studies and successful IND submission.

After a successful EOP2 meeting with the FDA in May 2019, Cloudbreak Therapeutics will proceed with Phase III clinical trial to develop a drug candidate which is a disease modifying, first-in-class, and the first drug therapy to treat pterygium. 

Cloudbreak Therapeutics operates a capital efficient business model based upon VIC + 505b(2). We repurpose approved systemic drugs for ocular delivery to treat eye diseases and quickly advance drug candidates to complete proof-of-concept (POC) Phase II clinical trials and to out-license global rights for Phase III clinical trials, product registration, and commercialization. Fully embracing the pharmaceutical development ecosystem, we utilize contract research organizations (CRO) for non-clinical, CMC and clinical development to efficiently maximize capital for drug development.

The Cloudbreak Therapeutics management team has over 50 years of combined experience with ocular drug discovery and development. In addition, Cloudbreak Therapeutics is supported by seasoned advisers and consultants.

Management

Jinsong Ni, PhD Cloudbreak Therapeutics Founder and CEO

Jinsong Ni, Ph.D

Founder, Chief Executive Officer

Van Dinh MBA Cloudbreak Therapeutics Co-Founder and COO

Van Dinh, MBA

Co-founder, Chief Operating Officer

Rong Yang, PhD Cloudbreak Therapeutics Chief Scientific Officer

Rong Yang, Ph.D

Chief Scientific Officer

Greg Brooks

Greg Brooks, B.Sc

Chief Business Officer

WenKui Fang

WenKui Fang, Ph.D

Chief Innovation Officer

Greg Brooks

Greg Brooks, B.Sc

Chief Business Officer

WenKui Fang

WenKui Fang, Ph.D

Chief Innovation Officer

Bing Leng

Bing Leng, MD

VP of Clinical Operations